간질 시장에 대해 조사했으며, 간질 치료의 동향에 관한 키 업계 리더의 최신 인사이트를 파악할 수 있습니다. 현재 치료법의 유효성, 신약의 가능성, 진화하는 관리 전략에 대해 심층 분석하고 있습니다. 미충족 요구 및 신규 치료의 벤치마크에도 언급하며, 간질 치료의 미래에 대해 종합적으로 정리하여 전해드립니다.
본 리포트의 주요 브랜드
Belviq(lorcaserin)
Briviact(brivaracetam)
Comfyde(carisbamate)
Diacomit(stiripentol)
Epidiolex/Epidyolex(cannabidiol)
EPX-100(clemizole)
EQU-001(ivermectin capsule formulation)
Fintepla(fenfluramine)
Fycompa(perampanel)
STK-001(zorevunersen)
TAK935(soticlestat)；Xcopri/Ontozry(cenobamate)
XEN1101(azetukalner)
Ztalmy(ganaxolone)
기업 리스트
UCB
Jazz Pharmaceuticals
SK Life Science
Takeda
Marinus Pharmaceuticals
Xenon Pharmaceuticals
Eisai
Stoke Therapeutics
Epygenix Therapeutics
Biocodex
Equilibre Biopharmaceuticals
KSA
영문 목차
영문목차
Discover the latest insights from key opinion leaders on epilepsy treatment trends. This report delves into the efficacy of current therapies, the potential of emerging drugs, and evolving management strategies. It addresses unmet needs and benchmarks for new treatments, offering a comprehensive view of the future landscape in epilepsy care.
Key questions answered:
How do current epilepsy treatments compare in terms of efficacy, side effects, and ease of use?
Which upcoming epilepsy therapies show the most potential for improving patient outcomes?
What benchmarks must new epilepsy drugs meet to remain competitive in the market?
How will new treatments impact the current landscape of epilepsy medications?
How is epilepsy management expected to evolve for different patient populations?
What are the key unmet needs in existing epilepsy treatments that still need to be addressed?
Key brands covered in this report:
Belviq (lorcaserin)
Briviact (brivaracetam)
Comfyde (carisbamate)
Diacomit (stiripentol)
Epidiolex/Epidyolex (cannabidiol)
EPX-100 (clemizole)
EQU-001 (ivermectin capsule formulation)
Fintepla (fenfluramine)
Fycompa (perampanel)
STK-001 (zorevunersen)
TAK 935 (soticlestat); Xcopri/Ontozry (cenobamate)
XEN1101 (azetukalner)
Ztalmy (ganaxolone)
List of Companies:
UCB
Jazz Pharmaceuticals
SK Life Science
Takeda
Marinus Pharmaceuticals
Xenon Pharmaceuticals
Eisai
Stoke Therapeutics
Epygenix Therapeutics
Biocodex
Equilibre Biopharmaceuticals
Table of Tables
Executive summary
Treatment algorithm
Research objectives
Marketed therapies
Sodium channel blockers
Carbamazepine-related antiseizure medications
Xcopri/Ontozry (cenobamate; SK Life Science)
Neuromodulators
Briviact (brivaracetam; UCB)
Key insights summary
GABAergic mechanisms
Benzodiapines (rescue medications)
Key insights summary
Ztalmy (ganaxolone; Marinus Pharmaceuticals)
Diacomit (stiripentol; Biocodex)
Other modes of action
Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals)
